LexaGene Announces Webinar by UC Davis Professor on Use of MiQLab® System for Diagnosis of Urinary Tract Infections
BEVERLY, Mass., July 05, 2022 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab System for automated, multiplexing PCR-based syndromic testing in veterinary clinics, is pleased to announce that University of California-Davis (UC Davis) Professor Dr. Jane Sykes BVSc (Hons), PhD, MBA, DACVIM (SAIM) will present a webinar entitled, “The Wave of the Future: In-Clinic PCR Diagnosis.” This will be a live event hosted by DVM360 and moderated by Adam Christman, DVM, MBA. It is scheduled for Tuesday July 26th at 7 PM EST. To register for the webinar, please click HERE.
This webinar will provide background information on the difficulties of accurately diagnosing urinary tract infections with conventional technologies. Also, the course will provide background information on the rising threat of antimicrobial resistance. This will be followed by an overview of PCR and how genomic testing can be used by veterinarians to make rapid evidence-based decisions in the clinic by utilizing the MiQLab System to rapidly screen samples for 10 common pathogens and 33 markers for antimicrobial resistance factors.
Dr. Sykes is a Professor of Small Animal Internal Medicine (Infectious Diseases) and the Executive Director of Innovation and Entrepreneurship in the School of Veterinary Medicine (SVM) at UC Davis. Her research focus is infectious diseases of dogs and cats, especially those of public health significance.
Dr. Sykes hails from Melbourne, Australia. Dr. Sykes received her veterinary degree and PhD at the University of Melbourne and her MBA from the University of Georgia. She completed her residency at the University of Minnesota. Dr. Sykes is a Diplomate of the American College of Veterinary Internal Medicine (SAIM) and has a California University Veterinarian Licensure. She is the recipient of numerous awards and author of many scientific publications.
To learn more about LexaGene and the MiQLab System or subscribe to company updates, visit www.lexagene.com, or follow us on Twitter or LinkedIn.
On Behalf of the Board of Directors
Dr. Jack Regan
Chief Executive Officer & Chairman
To learn more about LexaGene and the MiQLab System or subscribe to company updates, visit www.lexagene.com, or follow us on Twitter or LinkedIn.
For inquiries: 800.215.1824 | ir@lexagene.com or info@lexagene.com
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab® system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
